Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration

Jae Kyu Ryu(Gladstone Institutes), Katerina Akassoglou(Gladstone Institutes), Dimitrios Davalos(Cleveland Clinic), Veena Menon(Lundbeck (United States)), Kim M. Baeten(Gladstone Institutes), Pamela E. Rios Coronado(Gladstone Institutes), Suresh B. Poda(Lundbeck (United States)), Raymond A. Swanson(San Francisco VA Medical Center), Michael R. Machado(Gladstone Institutes), Mark A. Petersen(Gladstone Institutes), Scott S. Zamvil(University of California, San Francisco), Michelle R. Arkin(University of California, San Francisco), Andrew S. Mendiola(Gladstone Institutes), Hiroyuki Hakozaki(University of California San Diego), Mark H. Ellisman(University of California San Diego), Jeffrey B. Stavenhagen(Lundbeck (Denmark)), Kristina Hanspers(Gladstone Institutes), Catherine Bédard(Gladstone Institutes), Catriona Syme(Gladstone Institutes), Ioanna Plastira(Gladstone Institutes), Lennart Mucke(Gladstone Institutes), Justin Chan(Gladstone Institutes), Alexander R. Pico(Gladstone Institutes), Kenneth K. Hallenbeck(University of California, San Francisco), Shoana L. Sikorski(University of California San Diego), Sophia Bardehle(Gladstone Institutes), Stephen B. Freedman, Anke Meyer‐Franke(Gladstone Institutes), Stevin H. Zorn(Lundbeck (United States)), Kenny K. H. Ang(University of California, San Francisco), Samuel J. Pfaff(University of California, San Francisco), Lars Østergaard Pedersen(Lundbeck (Denmark)), Victoria A. Rafalski(Gladstone Institutes), Ryan A. Adams(aTyr Pharma (United States)), Robert B. Nelson(Lundbeck (United States))
Nature Immunology
October 11, 2018
Cited by 210


Related Papers